Nkarta Rg
Nkarta, Inc. develops CAR‑NK cell therapies targeting CD19, with lead candidate NKX019 in Phase I for lupus nephritis, systemic sclerosis and other autoimmune disorders. Partnering with CRISPR Therapeutics.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical and Diagnostic Laboratories
- Employees: 105
- HQ: South San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.